Company: PTHS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001753926-25-000790
Chunk: 21

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
 —

    —

    Non-vested
    at March 31, 2025

    460,770

    $
    2.51

    Non-vested
    Options
     
    Options

    Weighted-
    Average
    Exercise
    Price

    Non-vested
    at December 31, 2023

    113,429

    $
    22.68

    Granted

    —

    —

    Vested

    (43,592
    )

    22.68

    Forfeited

    —

    —

    Non-vested
    at March 31, 2024

    69,837

    $
    22.68

The
total number of options granted during the three months ended March 31, 2025 and 2024 was 0 and 0, respectively.

The
Company recognized stock-based compensation expense related to option vesting amortization of $403,921 and $292,552 for
the three months ended March 31, 2025 and 2024, respectively, which is included in general and administrative expenses in the
consolidated statements of operations.

As
of March 31, 2025, the unamortized stock option expense was $891,399. As of March 31, 2025, the weighted average period for the
unamortized stock compensation to be recognized is 1.07 years.

Warrants

The
following is an analysis of the stock warrant grant activity:

    Weighted
    Average

    Weighted
    Average

    Number
    of
    Shares

    Exercise
        Price

    Remaining
    Life

    Stock
    Warrants

    Outstanding
    December 31, 2024

    55,000

    $
    7.50

    4.13

    Granted

    —

    —

    —

    Expired

    —

    —

    —

    Exercised

    —

    —

    —

    Outstanding
    March 31, 2025

    55,000

    $
    7.50

    3.88

    Exercisable
    March 31, 2025

    55,000

    $
    7.50

    3.88

    17

    Weighted
    Average

    Weighted